Enliven Therapeutics (ELVN) Interest Expenses (2019 - 2026)
Enliven Therapeutics (ELVN) posted Interest Expenses of $104000.0 for Q1 2026, down 11.11% sequentially from $117000.0 in Q4 2025, and up 25.3% YoY from $83000.0 in Q1 2025.
Enliven Therapeutics (ELVN) Interest Expenses (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Interest Expenses for 8 years, with the latest figure at $104000.0 in Q1 2026.
- Quarterly Interest Expenses rose 25.3% year-over-year to $104000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $348000.0 (up 16.78% YoY) and the FY2025 annual result came in at $27.8 million, down 59.82% from the prior year.
- Interest Expenses slipped to $104000.0 in Q1 2026 per ELVN's latest filing, from $117000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $42.8 million in Q4 2023 and troughed at $20000.0 in Q1 2023.
- A 5-year average of $3.9 million and a median of $117000.0 in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2024: Interest Expenses surged 42402.17% in 2022, then tumbled 99.9% in 2024.
- Over 5 years, Interest Expenses stood at $19.6 million in 2022, then jumped by 118.84% to $42.8 million in 2023, then sank by 99.9% to $44000.0 in 2024, then soared by 165.91% to $117000.0 in 2025, then retreated by 11.11% to $104000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $104000.0, $117000.0, and $514000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | 1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.91 Mn |
| Jun 30, 2026 | 1.91 Mn |
| Mar 31, 2026 | 104,000.00 |
| Mar 31, 2026 | 104,000.00 |
| Dec 31, 2025 | 117,000.00 |
| Dec 31, 2025 | 117,000.00 |
| Sep 30, 2025 | 514,000.00 |
| Sep 30, 2025 | 514,000.00 |
| Jun 30, 2025 | 614,000.00 |
| Jun 30, 2025 | 614,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Dec 31, 2024 | 44,000.00 |
| Dec 31, 2024 | 44,000.00 |
| Sep 30, 2024 | 86,000.00 |
| Sep 30, 2024 | 86,000.00 |
| Jun 30, 2024 | 85,000.00 |
| Jun 30, 2024 | 85,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Mar 31, 2024 | 85,000.00 |